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Abstract
Introduction: HIV infection is characterized by a persistent immune activation
associated to a compromised gut barrier immunity and alterations in the profile of
the fecal flora linked with the progression of inflammatory symptoms. The effects
of high concentration multistrain probiotic (Vivomixx1, Viale del Policlinico 155,
Rome, Italy in EU; Visbiome1, Dupont, Madison, Wisconsin in USA) on several
aspects of intestinal immunity in ART-experienced HIV-1 patients was evaluated.
Methods: A sub-study of a longitudinal pilot study was performed in HIV-1
patients who received the probiotic supplement twice a day for 6 months (T6).
T-cell activation and CD4þ and CD8þ T-cell subsets expressing IFNg (Th1, Tc1)
or IL-17A (Th17, Tc17) were stained by cytoflorimetric analysis. Histological and
immunohistochemical analyses were performed on intestinal biopsies while
enterocytes apoptosis index was determined by TUNEL assay.
Results: A reduction in the frequencies of CD4þ and CD8þ T-cell subsets,
expressing CD38þ, HLA-DRþ, or both, and an increase in the percentage of Th17
cell subsets, especially those with central or effector memory phenotype, was
recorded in the peripheral blood and in gut-associated lymphoid tissue (GALT)
after probiotic intervention. Conversely, Tc1 and Tc17 levels remained substantially
unchanged at T6, while Th1 cell subsets increase in the GALT. Probiotic
supplementation was also associated to a recovery of the integrity of the gut
epithelial barrier, a reduction of both intraepithelial lymphocytes density and
enterocyte apoptosis and, an improvement of mitochondrial morphology sustained
in part by a modulation of heat shock protein 60.
Conclusions: These findings highlight the potential beneficial effects of probiotic
supplementation for the reconstitution of physical and immunological integrity of
the mucosal intestinal barrier in ART-treated HIV-1-positive patients.
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Introduction
Damage to the intestinal epithelium with enterocyte
apoptosis and compromising tight junction complexes,
massive depletion of CD4þ T-cells in gastrointestinal (GI)
tract, and preferential decrease of Th17 cells from GI tract
contributes significantly to translocation of commensal
microbial products from gut into circulation which is
considered a major driver of chronic immune activation in
HIV-1-infected humans and in the experimental model SIV-
infected rhesus macaques (RMs) [1–3]. In chronically SIV-
infected RMs, microbial translocation occurs during the late
stage of acute SIV infection and is associated with epithelial
damage of the GI tract and an inability of macrophages in
intestinal lamina propria to phagocytose translocated
microbial constituents [4]. Conversely, in the chronic phase
of SIV infection in sooty mangabeys, no evidence of
breakdown in intestinal epithelial barrier, no enhancement
of bacterial translocation, and no chronic immune activa-
tion are observed [4–6]. Given the strong relationship
between the impairment of GI tract and the presence of
various alterations in gut microbiota (dysbiosis) during
chronic HIV-1 infection [7–10], the development of adjunc-
tive strategies aimed at recovering the intestinal homeostasis
could benefit HIV-1-infected individuals, particularly those
on antiretroviral therapies. In this regard, the administration
of oral probiotic alone or in combination with interleukin-
(IL) 21 promotes increased reconstitution of intestinal CD4þ
T-cell during ART supplementation in SIV-infected mac-
aques [11]; interestingly, the effects on Th17 cell subset
frequency were different depending on whether the probiotic
were taken alone or in combination with IL-21 [11, 12].
Macaques treated with a Lactobacillus-containing formula-
tion showed also a decreased IDO1 activity improving the
preservation of Th17 cells during pathogenic SIV infec-
tion [13]. Most of our understanding on potential benefits
imparted to HIV-1-positive individuals by dietary supple-
mentation with probiotics are derived from animal models of
lentiviral disease or from the evaluation of the systemic effects
of probiotic [11–17] and only few studies have focused
analyses on gutmicrobiota [18–23], gastrointestinal anatomy,
and physiology [21] and potential benefits of probiotic
administration in HIV-1-infected patients. Although ART
subjects might benefit from probiotic supplementation, these
individuals might also be at risk for unexpected adverse
reactions such as sepsis and the limited understanding about
the mechanisms of probiotics action is a major drawback for
the prediction of probiotic safety [24]. Herein, we decided to
carry on a pilot study to assess the safety and efficacy of a
probiotic supplementation selecting for the supplementation
to ART patients a high concentration multi strain probiotic
mixture (Vivomixx1 in Europe; Visbiome 1 in USA) which
has been extensively used in diseases characterizedbymucosal
ulceration and exposure of the submucosa, that is, inflam-
matory bowel diseases [25, 26]. The aim of the study was also
to verify whether this preparation could play a role in
restoring GI tract immunity and intestinal barrier integrity
with consequent reduction of inflammation and enhance-
ment of the recovery of CD4þ T cells and, in particular,
Th17 cells. We observed that this dietary management is
associated with increased frequencies of mucosal and
systemic Th17 cells and a strong decrease in T-cell
activation. Furthermore, we provide, for the first time to
our knowledge, direct in vivo evidence that this specific
probiotic supplementation caused profound histomorpho-
logical tissue changes in the intestinal epithelium of HIV-
1-infected patients and identify the recovery of the integrity
of the gut epithelial barrier strictly dependent to a
reduction of both intraepithelial lymphocytes (IELs)
density and enterocyte apoptosis and an improvement of
mitochondrial morphology sustained in part by a modula-
tion of heat shock protein 60 (HSP60) protein expression.
These findings underscore the benefits and safety of this
specific formulation as adjunctive and practical interven-
tion for the reconstitution of physical and immunological
integrity of the mucosal intestinal barrier and reducing
systemic T-cell immune activation in ART-treated HIV-
1-positive patients, at least in this pilot study.
Materials and Methods
Study design, recruitment, and study eligibility
criteria
This is a sub-study of a pilot longitudinal, non-randomized
designed, single arm study (clinicaltrials.gov registry
[number NCT02276326]; Consort Checklist [Supplemen-
tary Fig. S1], and Flow Diagram [Supplementary Fig. S2])
including 10 HIV-1-positive patients because we had to be
sure about the safety of the tested probiotic.
Patients were selected for the present study, if they met the
following inclusion criteria: (i) who had signed the informed
consent; (ii) men or women at least 18 years of age; (iii) in
ART; and (iv) with HIV-1 RNA<37 copies/mL and CD4þ T
counts >400 cells/mm3. Exclusion criteria included: (i)
known or suspected allergy or intolerance to the specific
probiotic formulation; (ii) use of probiotics or antibiotics
during the 3 weeks prior the enrollment; (iii) drug addiction;
(iv) history of or current inflammatory diseases of the small
or large intestine; (v) diarrhea; (vi) any current, past, or
systemic malignancy; and (vii) pregnancy.
From May 2014 to February 2015, 10 HIV-1-positive
patients successfully ART-treated were recruited at the
Division of Infectious Diseases, Department of Public Health
and Infectious Diseases, Hospital of Sapienza University of
Rome (Italy).
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Patients received a high concentration lyophilized multi-
strain probiotic supplement (Lactobacillus plantarum
DSM24730, Streptococcus thermophilus DSM24731, Bifido-
bacterium breve DSM24732, L. paracasei DSM24733, L.
delbrueckii subsp. bulgaricusDSM24734, L. acidophilusDSM
24735, B. longumDSM24736, B. infantisDSM24737) twice a
day for 6 months. This formulation is now commercialized
as Vivomixx1; Visbiome1 [27]. The probiotic preparation
was administered per os at a daily dosage of 1.8 1012 live
bacteria.
The study was approved by the institutional review board
(Department of Public Health and Infectious Diseases,
Sapienza University of Rome) and the Ethics Committee
(Sapienza University of Rome) on 16 January 2014. All study
participants signed written informed consent. No adverse
event was observed during the follow-up and all subjects
maintained undetectable plasmatic viral load before and
after probiotic assumption (HIV-1 RNA [< 37 copies/mL]).
Laboratory procedures
All patients underwent endoscopic procedures and blood
collection prior to initiation of probiotic supplementation
(T0) and after 6 months (T6). Colonic washing was carried
out by PEG administration 24 h before the examination. The
endoscopic procedure was performed with conscious
sedation (midazolam 5mg/iv) using large cup forceps
(Radial Jaw 4, Boston Scientific, Natick, MA). All individuals
underwent a total colonoscopy and retrograde ileoscopy for
at least 10 cm of distal ileum with conventional or slim scope
(model CF or PCF-160 AI, OlympusMedical Europe GmbH,
Hamburg, Germany). Specimens (two biopsies from each
site) from the terminal ileum, cecum, ascending, transverse,
and descending colon were obtained. Additionally, biopsies
for histology and immunohistochemistry evaluations were
collected. Lastly, fecal samples were collected before and
after 2 and 6 months of probiotic supplementation. T-cell
phenotype and activation markers were analyzed on freshly
isolated peripheral blood mononuclear cells (PBMCs) and
lamina propria lymphocytes (LPLs). T-cells subpopulation
and cytokine expression were evaluated after overnight-cell
culture.
Specimen processing
Twenty milliliters of whole blood were collected by
venipucture in Vacutainer tubes containing ethylenediami-
netetraacetic acid (BD Biosciences, San Jose, CA) at each
study visit. Plasma was immediately separated by centrifu-
gation and stored at 808C for further analysis.
PBMCs were separated on Ficoll gradient centrifugation
(Lympholyte, Cedarlane Labs, Hornby, Ontario, Canada),
and washed twice in phosphate-buffered saline. Freshly
isolated PBMCs were used immediately for immune
phenotyping and activation staining or overnight cultured
for stimulation. Biopsies from intestinal sites were mixed
with each other and processed. Briefly, biopsies collected in
RPMI 1640 (heat inactivated 10% fetal bovine serum) were
washed twice with EDTA wash media, resuspended, and
incubated for 1 h at room temperature in EDTA solution
5mM on automatic shaker. Supernatant containing intra-
epithelial lymphocytes was removed, and biopsies were
digested by 1-h incubation at 378C in pre-warmed RPMI
1640 (heat inactivated 10% fetal bovine serum) with 1mg/
mL collagenase (Sigma–Aldrich, Milan, Italy) and 1.5U
DNAse I (Sigma–Aldrich), bringing to the isolation of LPLs,
then filtered through a 70mm cell strainer (Becton
Dickinson).
Cell cultures
PBMCs and LPLs were seeded at concentrations of 2 106
cells/mL and 1.5 106 cells/mL, respectively, with RPMI
media plus 20% heat inactivated fetal bovine serum (FBS)
and incubated overnight at 378C and 5%CO2 in the presence
of medium alone or supplemented with phorbol myristyl
acetate (PMA) (3 ng/mL, Sigma–Aldrich) and ionomycin
(1mg/mL, Sigma–Aldrich). BD GolgiStop (Becton Dick-
inson) was added to all culture conditions. Cells were then
collected, washed, permeabilized, and stained for T-cell
phenotype and cytokine expression.
Monoclonal antibody and T-cell phenotyping
Phenotype and activation were evaluated by 7-color flow
cytometric analysis on freshly isolated PBMCs and LPLs
using the following anti-human monoclonal antibodies:
CD3-PerCP, CD4-APC-Vio770, CD8-FITC, CD45RO-
PEVio770, CD27-VioBlue, CD38-APC, and HLA-DR-PE
(Miltenyi Biotec, Bergisch Gladbach, Germany). Gating
strategy for flow cytometry analysis of peripheral blood and
GALT is provided in Supplementary Figure S3. T-cell
subpopulations were identified according to the following
phenotypic combinations: CD27þCD45ROþ (Central
Memory) and CD27CD45ROþCD4þ (Effector Memory)
cells. Cultured cells were fixed, permeabilized (BD Cytofix/
Cytoperm, Becton Dickinson), and stained with combina-
tions of surface and intracellular fluorochrome-labeled
monoclonal antibodies: CD3-PerCP, CD4-APC-Vio770,
CD8-FITC, CD45RO-PE-Vio770, CD27-VioBlue, IFNg-
APC, and IL-17A-PE (Miltenyi Biotec).
CD3þCD4þ cells expressing IFNg or IL-17A were
identified as Th1 and Th17, respectively; CD3þCD8þ cells
expressing IFNg or IL-17A were identified as Tc1 and Tc17,
respectively.
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Acquisitions were performed on Miltenyi Biotec flow
cytometer-MACSQuant Analyzer (eight fluorescence chan-
nels, three lasers). Gating analysis and data were analyzed
using MACSQuantify software 2.5 (Miltenyi Biotec). The
same gating strategy was applied to all samples. At least
100,000 and 10,000 events in the CD3þ lymphocytes gate
were analyzed for PBMCs and LPLs, respectively. Isotype
controls were used as negative controls to differentiate non-
specific background signal from specific antibody signal of
CD38, HLA-DR, IL-17A, and IFNg markers.
Real-time PCR assay for bifidobacteria
Bacterial DNA from fecal samples collected before and after
2 and 6 months of probiotics supplementation was extracted
using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden,
Germany) as previously reported [28]. Then, real-time PCR
was performed evaluate bifidobacteria levels as previously
described [28, 29]. Briefly, PCR amplification and detection
were performed on optical-grade 96-well plates using the
Applied Biosystems 7500 Real-Time PCR instrument
(Applied Biosystems, Inc., Norwalk, Conn). The reaction
mixture (25mL) was composed of SensiMix SYBR Low-
ROX (BIOLINE, Taunton, MA), 500 nM primers for
Bifidobacterium genus, and 2.5mL of template DNA. A
melting curve analysis was made after amplification to
distinguish target amplicons from aspecific non-target PCR
products. Standard curves were made by using 10-fold
dilutions of DNA extracted from Bifidobacterium breve.
All samples were analyzed in duplicate in two independent
real-time PCR assays.
Virological analysis
HIV-1 RNA copy number was measured in plasma by
using Versant kPCR (Siemens Healthcare Diagnostic, Inc.,
Tarrytown, NY). The detection limit was 37 HIV-1 RNA
copies/mL.
Histological analysis
Histological score analysis of HIV-1-positive patients was
performed at T0 and T6 to grade: (i) the amount of immune
cells infiltration; (ii) the amount of intra-epithelial lym-
phocytes (IELs); and (iii) GALT (Peyer patches) activation.
Histological analysis comprehended the estimation of
cellular infiltrates and aggregation by scoring the number
of macrophages, lymphocytes, plasma cells, and neutrophils
at 400 magnification. The inflammatory cells number was
measured with a semiquantitative method [30–32] and
results are provided as the mean for the entire specimen. In
the presence of strong intensity variation of infiltration in the
same specimen, the mean for several areas was determined
and the specimen was scored accordingly. Neutrophils and
macrophages were classified as absent (score 0) when there
were no or fewer than 19 cells per high-power field (HPF) (at
a 400 magnification), mild (score 1) for 20–49 cells per
HPF, moderate (score 2) for 50–99 cells per HPF, marked or
severe (score 3) for 100–200 cells or more per HPF.
Histological criteria for normal intestinal features included
detection of only a few mononuclear cells in transcytosis
across epithelium per HPF, as IELs and no, or only a few
scattered neutrophils in the axis of villi and/or between
the crypts without tissue changes (no interstitial thickening
or aggregates of lymphocytic infiltrates, and lumen free
from exudate). The number of inflammatory cells and
of lymphoid aggregates was assessed at 400 and 100
magnification, respectively, and was scored as described by
Dixon et al. [33]. For GALT activation, the score was assessed
at 100 magnification, by calculating the total areas of
GALT follicles evaluated inside each intestinal section, and
subdividing the mean as follow: mean area of GALT follicle
extension; score 0, none; score 1, up to 0.008mm2; score 2,
up to 0.042mm2; score 3, up to 0.4mm2.
Immunohistochemical evaluation
Tissues were fixed in 10% neutral buffered formalin (Sigma,
Milan, Italy) for paraffin embedding. Paraffin-embedded
sections were cut at 3mm, deparaffinized, rehydrate, and
incubated with the follow primary antibody: HSP60 (mouse
anti-human HSP60/Heat Shock Protein 60 Mab–2E1/53–
ThermoFisher, used at 1:50 dilution). Subsequently, rehy-
drated sections were treated for endogenous peroxidases
neutralization with 3% hydrogen peroxide for 5min
followed by rinsing for 5min in distilled water. Antigen
retrieval was achieved by incubating slides in citrate buffer
(pH 6.0) according to antibody datasheet, in a steamer
(Black & Decker, Towson, MD) for 20min. Non-specific
immunoglobulin binding was blocked by incubation of
slides with a nonspecific staining protein-blocking reagent
(DakoCytomation, Carpinteria, CA) for 20min, before
application of the primary antibody, used at the optimal
dilutions, overnight at 48C. After the incubation with
biotinylated secondary antibodies (goat anti-mouse IgG–
AO433; DAKO, used diluted 1:200), the resultant immune
complexes were visualized by the ABC Elite kit (Vector
Laboratories, Burlingame, CA) and peroxidase substrate
3,30-diaminobenzidine kit (Vector Laboratories) according
to the manufacturer’s instructions. Then, the slides were
counterstained with hematoxylin, dehydrated, and cover
slipped. For scoring antigens-positive cells, stained cells were
quantified in different intestinal compartments (villus,
apical crypt area, basal crypt area). All cellular types were
calculated using a light microscope (Carl Zeiss), at 40
objective, a 10 eyepiece, and a square eyepiece reticule
Probiotic and HIV-1-infected patients G. d’Ettorre et al.
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(10 10 squares, with a total area of 62,500mm2). Five sites
were chosen for each compartment and arithmetic means
were calculated for each intestinal region. Results were
expressed as immunohistochemistry-positive cells per
62,500mm2.
TUNEL for apoptosis evaluation
For the in situ detection of epithelial and lymphocytes
apoptotis, terminal deoxynucleotidyl transferase-mediated
digoxigenindeoxyuridine triphosphate nick-end labeling
(TUNEL) was performed on histological sections of
endoscopic ileal and colonic biopsy specimens collected
from all HIV-1-positive patients, [34, 35]. The sections were
digested with proteinase K treatment, 20mg/mL (Sigma
Chemical, St Louis, MO) for 15min at RT. After digestion,
the sections were washed in tap water. Further, endogenous
peroxidase activity was quenched with 3% hydrogen
peroxidase for 20min and then washed in PBS. After
equilibration, the sections were incubated at 378C in a
humidified chamber for 1 h in terminal deoxynucleotidyl
transferase (TdT) enzyme and then placed in stop/wash
buffer for 30mins. Next, the sections were rinsed in PBS
and, thereafter, treated with antidigoxigenin peroxidase for
30mins in a humidified chamber. Color on apoptotic nuclei
was developed using diaminobenzidine and hydrogen
peroxide for 1–3min. Finally, sections were counterstained
with Harris hematoxylin. As a positive control, an ApopTag
control slide was used, whereas negative control was
prepared by omitting the TdT enzyme from the nucleotide
mix on seriate sections. Counts were assessed, at a 200
magnification, by computer-assisted analysis and the results
were expressed asmedian percentages of positive enterocytes
or lymphoid cells inside epithelia or GALT follicles.
Transmiss ion e lect ron microscopy and
immunogold labeling
A small fragment of each intestinal section was cut into small
pieces (<1mm3) and fixed for 60min at 48C in periodate-
lysine-paraformaldehyde fixative (PLP) [36]. Pieces of tissue
were washed three times in 50mM Sorensen’s phosphate
buffer, 200mM sucrose, and 100mM lysine monochlorhy-
drate for 20min,at 48C, dehydrated through a series of
ethanol washes (50%, 70%, 95%, 100%), and infiltrated with
1:1 pure ethanol: London Resin (LR) White for 60min,
followed by pure LRWhite, three times for 60min at 48C.
Next, the specimens were embedded in gelatine capsules
filled with LRWhite and polymerized at 508C for 48 h. All of
the ultrathin sections (<80 nm) were microtomed with an
RMC MTX ultra microtome (Elexience), placed on
200mesh nickel grids coated with polylysine (dilition
1:1000), and stabilized for 1 day at RT. For immunogold
labeling, section grids were floated on drops of reactive
media. Non-specific binding sites were coated with 1% BSA
and 1% normal goat serum for 60min at RT. Next, antibody
incubation was carried out at 48C overnight in a wet
chamber with mouse anti HSP60 antibody (dilution 1:100).
in 1% BSA, 50mM Tris–HCl, pH 7.4. Tissue sections were
successively washed three times in 50mM Tris–HCl, pH 7.4,
and pH 8.2 at RT. They were then incubated in a wet
chamber for 45min at RT in 1% BSA, 50mM Tris–HCl, pH
8.2, and labeled with 10 nm gold conjugated goat anti-mouse
IgG ([Tebu] dilution 1:25) in 1% BSA, 50mMTris–HCl, pH
8.2. After three washing in 50mM Tris–HCl, pH 8.2 and pH
7.4. and in filtrated distilled water, the sections were then
contrasted with aqueous solution of uranyl acetate followed
by lead citrate before examining in transmission electron
microscope (Jeol 1200EX, Tokyo, Japan) equipped with a
MegaViewII digital camera and AnalySIS software (Eloise).
Statistical analysis
Statistical analyses were performed using SPSS software,
version 22.00 (IBM, Somers, NY) on data obtained from
peripheral blood, gut, and stool samples of HIV-1-positive
patients before and after probiotic supplementation. Data
obtained at T0 and T6 analysis in peripheral blood and
intestinal districts were compared by Wilcoxon test for
paired samples. The same test was also used to evaluate data
obtained from stool samples at T0, T2, and T6. Results are
given as medians, ranges, and percentages. P values <0.05
were considered statistically significant. All graphs were
generated by using GraphPad Prism (version 5.00).
Results
Participant characteristics
All of the study participants were Caucasian men (age
[median/range]: 42/22–53 years). They started ART during
chronic HIV-1 infection (baseline CD4þ T-cell count
[median/IQR]: 255/42.75–406.75 cells/mm3, baseline HIV-1
RNA copies [median/IQR]: 5.0/4.81–5.61 Log/mL). At study
enrolment all HIV-1-positive patients received antiretroviral
therapy for a median of 6 years (IQR, 1.75–16.25 years); all
patients had been virologically suppressed (<37 HIV-1 RNA
copies/mL) for at least 1 year and median CD4þ T cell count
was 674 cells/mm3 (IQR, 564–824 cells/mm3).
Product tolerability, safety, and action
In all study participants, self-reported adherence to
probiotic supplementation was excellent, and no adverse
reactions were reported by the patients or identified by the
clinicians.
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All subjects maintained undetectable plasmatic viral load
after probiotic assumption and the median CD4þ T-cell
count was 683 cells/mm3 (IQR, 610–818 cells/mm3).
To assess whether all HIV-1-infected patients had been
compliant with the protocol, we measured levels of
Bifidobacteria spp. in stool samples collected before and
after 2 and 6 months of probiotic supplementation We
found that fecal Bifidobacteria spp. increased significantly in
all patients, compared to their basal level, from two months
of supplementation (P¼ 0.019) and remained stable
throughout the study (Fig. 1) confirming adherence of the
patients to the regimen.
Baseline CD4þ and CD8þ T-cells subpopulations
In HIV/SIV-infected individuals, subtle T-cell phenotypic
differences have been described within small intestinal versus
large intestinal T-cell populations but most important is the
dramatic depletion of the CD4þ T cells in both anatomical
sites [37]. Consequently, to have a number of T cells
sufficient for flow cytometry subsets analysis, the cells
isolated from the large and small intestinal biopsies were
combined together. In particular, we measured, at baseline,
the CD4þ and CD8þ T-cell frequencies in peripheral blood
and GALT and the frequencies of particular subsets of
memory T-cells. We found no statistical difference in CD4þ
T-cells frequencies between peripheral blood and GALT
(39.5; IQR 26.9–52.8 and 45.7; IQR 40.9–63.04, respectively;
P¼ 0.5). As expected, most of the CD4þ T-cells in GALT
showed a central memory (CM: CD4þCD27þCD45ROþ)
phenotype (85.2, IQR 82.9–86.3) and their percentage was
higher than in peripheral blood (47.3, IQR 34.5–61.2;
P¼ 0.005); the frequencies of effector memory (EM:
CD4þCD27CD45ROþ) CD4þ T-cells were similar in
peripheral blood and GALT (7.5; IQR 5.7–12.6 and 10.9;
IQR 8.5–13.2, respectively; P¼ 0.2).
CD8þ T-cell frequencies were similar in peripheral blood
and GALT (54.8; IQR 40.4–63 and 44.7; IQR 36.9–49.5,
respectively; P¼ 0.14); the percentage of CM CD8þ T-cells
(CD8þCD27þCD45ROþ)was higher inGALT thanperipheral
blood (78.7; IQR72.6 and 80; 26.1; IQR20.7–41.3, respectively;
P¼ 0.0001); EM CD8þ T (CD8þCD27CD45ROþ) cells
frequencies were similar in peripheral blood and GALT (17.4;
IQR 10.6–28.7 and 13.11; IQR 10.6–16.1; P¼ 0.2).
Changes of T-cell activation in peripheral blood
after 6 months of probiotic supplementation
The three possible expression patterns of the T-cell
activation markers HLA-DRþ and CD38þ (CD38þHLA-
DR, CD38-HLA-DRþ, and CD38þHLA-DRþ) were ana-
lyzed in CD4þ or CD8þT-cell subsets from peripheral blood
of HIV-1-infected patients before and after probiotic
supplementation. As seen from Figure 2A, B, D, and E,
the frequencies of CD4þ and CD8þ T-cells expressing
alternately CD38 or HLA-DR were significantly lower after
probiotic supplementation (respectively CD4þ T-cells:
P¼ 0.005 and P¼ 0.005; CD8þ T-cells: P¼ 0.037 and
P¼ 0.005). Also the proportion of CD4þ or CD8þ T-cells
simultaneously expressing HLA-DR and CD38 significantly
decreased after 6 months of probiotic supplementation
(CD4þ T-cells: P¼ 0.008 and CD8þ T-cell: P¼ 0.037;
Fig. 2C and F). Similar results were obtained comparing
the frequencies of activated EM CD4þ or CD8þ T-cell
subsets (Fig. 2A–F). Additionally, a significant reduction of
CM CD4þCD38þHLA-DR and CM CD4þCD38þHLA-
DRþ T-cells at T6 was noticed (P¼ 0.007 and P¼ 0.037,
respectively; Fig. 2A and C). Lastly, the CM CD8þ T-cells
with the CD38-HLA-DRþ or CD38þHLA-DRþ phenotype
also decreased after probiotic supplementation (P¼ 0.007
and P¼ 0.021, respectively) (Fig. 2E and F).
Changes of T-cell immune activation in GALT after
6 months of probiotic supplementation
>Subsequently, we evaluated the frequencies of CD4þ or
CD8þ T-cell subsets that expressed CD38þ, HLA-DRþ, or
both to determine whether a reduction of activated T-cells
occurred in GALT after probiotic supplementation. We
found a significant reduction in the frequencies of CD4þ and
CD8þ T-cells expressing alternately CD38þ HLA-DRþ or
Figure 1. Bifidobacteria in fecal samples of HIV-infected subjects at
enrolment (T0) and after 2 (T2) and 6 months (T6) of probiotic
supplementation. Box and whisker plots based on Log 16S rRNA gene
copies per gram of stool. The horizontal line in the middle of each box
represents the median, while the top and bottom borders of the box
represent the 75% and 25% percentiles, respectively. P< 0.05 (T0 vs.
T2); P< 0.05 (T0 vs. T6), using Wilcoxon test.
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both after probiotic supplementation (P¼ 0.005 for all the
comparisons, Fig. 2A–F). The only exception being the
frequencies of CD8þCD38-HLA-DRþ T-cells at T6, which
although was lower compared to those recorded at T0, the
difference did not reach the statistical significance (P¼ 0.139,
Fig. 2E). The percentage of EM CD4þ T-cell subpopulations
also decreased (P¼ 0.037, Fig. 2A–C) as well as the percentages
of EM CD4þ T-cell expressing the CD38þ activation marker
after probiotic supplementation (P¼ 0.005; Fig. 2A).
Additionally, the frequencies of CM and EMCD8þ T-cells
subpopulations with CD38þ or CD38þHLA-DRþ pheno-
type were also significantly lower after probiotic assumption
(CM: P¼ 0.005 and P¼ 0.005; EM: P¼ 0.005 and P¼ 0.038,
respectively; Fig. 2D and F).
Changes of Th17, Th1, Tc17, and Tc1 frequencies
in peripheral blood and GALT after 6 months of
probiotic supplementation
To assess whether probiotic supplementation promote a
recovery of Th17 cells, we measured the frequencies of Th17
in peripheral blood and GALT at T0 and T6. We found a
trend toward an increase in the percentage of total Th17 cells
both in peripheral blood and GALT after probiotic
supplementation (respectively P¼ 0.059 and P¼ 0.059;
Fig. 3B). However, a significant improvement in the
frequencies of CM and EM Th17 cells was recorded at T6
both in both the anatomical sites (peripheral blood:
P¼ 0.028 and P¼ 0.037, respectively; GALT: P¼ 0.007
and P¼ 0.011, respectively, Fig. 3B). Then, we examined the
changes in the relative frequencies of Th1, Tc17, and Tc1
cells subsets before and after probiotic supplementation. No
significant differences between T0 and T6 were noted in the
percentage of Th1, Tc17, and Tc1 cells in peripheral blood
(Fig. 3A, C, and D). However, the percentage of EM Tc1 was
higher at T6 respectively in the GALT and peripheral blood
(P¼ 0.013, P¼ 0.005, respectively; Fig. 3C).
Conversely, a strong increase of total Th1 cells was
observed at T6 in GALT (P¼ 0.005, Fig. 3A) and, again,
higher relative frequencies of CM and EM, Th1 cell subsets
were noted in this anatomical site (P¼ 0.059, P¼ 0.047, and
P¼ 0.047, respectively; Fig. 3A).
Figure 2. Percentage of CD4þ (A–C) andCD8þ T (D–F) cell subsets (total [TOT], centralmemory [CM], and effectormemory [EM]) expressing CD38þ and
HLA-DRþ (CD38þ HLA-DR, CD38þ HLADRþ, and CD38 HLA-DRþ) derived from peripheral blood and gut-associated lymphoid tissue (GALT) of ART-
treated HIV-1-positive patients (n¼ 10) before (T0) and after 6months (T6) of probiotic supplementation. Dot plots represent the frequencies of CD4þ T-
cell subsets that express CD38þ (A), HLA-DRþ (B), or both (CD38þHLA-DRþ, Panel C) in peripheral blood and in GALT (Wilcoxon test for paired samples ,
, and  ¼ P< 0.05). Dot plots represent the frequencies of CD8þ T-cell subsets that express CD38þ (D), HLA-DRþ (E), or both (CD38þHLA-DRþ, Panel
F) in peripheral blood and in GALT (Wilcoxon test for paired samples *, ** and ***¼ P< 0.05).
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Changes in gut histology and morphology after
6 months of probiotic supplementation
The observation of increased frequencies of intestinal Th17
cells and decreased T-cell activation after supplementation
raises the possibility that probiotic administration might
also promote the reversing of gut damage in HIV-1
infection. To directly pursue this possibility, we performed
a histologic and morphologic analysis of GALT and
intestinal tract tissues before and after probiotic supplemen-
tation. We found that the histology score, evaluated before
the beginning of probiotic assumption (T0) and after
6 month (T6), generally decreased as demonstrated in
Figures 4 and 5. Remarkably, from a morphological point of
view, after the probiotic administration, sections of all tracts
of intestinal mucosa, regardless of the examined intestine
tract, showed an improvement of epithelial integrity, a
reduction of diffuse interstitial inflammatory infiltrate, and
an increase in the number and area of the GALT structures
associated to the mucosa (Figs. 4 and 5). Then, we evaluated
the inflammatory infiltrate in intestinal biopsies collected
before and after the probiotic supplementation, focusing on
intraepithelial lymphocytes (IELs) density. A general decline
in IELs counts in all intestinal tracts analyzed after probiotic
supplementation was recorded (Fig. 6). In particular,
the number of IELs was significantly lower at T6 compared
to those at T0 in the cecum (Fig. 6A), ileum (Fig. 6B),
transverse (Fig. 6D), descending colon (Fig. 6E) (P¼ 0.049,
P¼ 0.027, P¼ 0.004, and P¼ 0.002, respectively). A trend
toward a reduction in IELs numbers after probiotic
supplementation was also observed in the ascending colon
but the difference did not reach statistical significance
(P¼ 0.06, Fig. 6C).
Changes of enterocytes apoptosis and HSP60 levels
after 6 months of probiotic supplementation
Given that this specific probiotic supplementation seemed to
induce a recovery of intestinal integrity of epithelial barrier
and a reduction in IELs density, we examined whether
probiotic supplementation leads to reduce rate of enter-
ocytes undergoing apoptosis. As shown in Figure 7, we found
that the decline of IELs infiltrating the intestinal epithelium
after the probiotic supplementation was strictly associated to
a statistically significant decrease in the levels of apoptosis
index both in epithelium and intestinal crypts (P¼ 0.04).
Additionally, a decrease in the enterocyte levels of
cytoplasmic HSP60 protein was noticed. Indeed, comparing
the HSP60 levels in intestinal mucosa before and after the
probiotic assumption, a trend toward a reduction of HSP60
was found in cecum (Fig. 8A, T0: 82.70/19.85–129.8, T6:
23.80/11.65–112.20, P¼ 0.432) and ileum (Fig. 8B, T0:
93.40/33.65–120.4, T6: 18.70/9.45–92.80, P¼ 0.275), while
Figure 3. Percentage of CD4þ and CD8þ T-cell subsets (total [TOT], central memory [CM], and effectormemory [EM]) expressing IFNg (Th1 and Tc1) and
IL-17A (Th17 and Tc17) derived from peripheral blood and gut-associated lymphoid tissue (GALT) of ART-treated HIV-1-positive patients (n¼ 10) before
(T0) and after 6 months (T6) of probiotic supplementation. Dot plots represent the frequencies of expression of IFNg (Th1, Panel A) and IL-17A (Th17,
Panel B) CD4þ T-cell subsets in peripheral blood and in GALT (Wilcoxon test for paired samples , , and  ¼ P< 0.05). Dot plots represent the
frequencies of expression of IFNg (Tc1, Panel C) and IL-17A (Tc17, Panel D) CD8þ T-cell subsets in peripheral blood and in GALT (Wilcoxon test for paired
samples , , and  ¼ P< 0.05).
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the HSP60 median values decreased significantly after
probiotic supplementation in ascending (Fig. 8C), transverse
(Fig. 8D), and descending colon (Fig. 8E) (P¼ 0.01;
P¼ 0.037; P¼ 0.04, respectively).
At the same time, all the intestinal sections evaluated by
TEM, demonstrated that enterocytes regeneration after
probiotic supplementation was associated to a good
preservation of mitochondrial structure, and that the
reduction in intracytoplasmic expression of HSP60 was
related to a strong increase of intra-mitochondrial concen-
tration of this protein (Fig. 8F and G). In particular, HSP60
was detected closely related to the innermembrane, or free in
mitochondrial matrix, adjacent to the mitochondrial cristae;
at the same time, HSP60 was not detectable in a free
intracytoplasmic pattern inside enterocytes belonging to
different portions of intestinal mucosa. Furthermore, the
Figure 4. Histological section of descending colon (A and B) and ileum (C andD) fromHIV-1-positive patients before (T0) and after 6months of probiotic
supplementation (T6). A decrease in the interstitial inflammatory infiltrate and a restoring of the intestinal and colonic epithelium integrity were recorded
at T6 (see arrows). 10 enlargement.
Figure 5. Histological section of descending colon and ileum from HIV-1-positive patients before (T0) and after 6 months of probiotic supplementation
(T6). An improvement of colonic epithelium integrity (see black arrows) and a decrease in the lymphocyte transcytosis (A and B) were recorded at T6. A
strong expansion of the Peyer patches (see red arrow; C and D) and the appearance of the typical (clear area) was recorded in the ileum at T6. 20
enlargement.
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examined mitochondria were almost always found in the
‘‘orthodox’’ conformation, characterized by a relatively large
matrix volume and the inner boundary membrane (the non-
cristae component of the inner membrane) closely opposed
to the outer membrane with a small space between them.
Discussion
Given the contributions of microbial dysbiosis and preferen-
tial depletion of Th17 cells to GI tract injury, microbial
translocation, and persistent immune activation [38–40], we
considered that supplementing ART therapy in HIV-
1-infected patients with probiotic mixture might favor a
restoration of the composition of the commensal gut
microbiota, beginning a sequence of immune and gut
physiology restorative processes. We assessed longitudinally
the effects of the probiotic supplementation on several
aspects of gut mucosal immunity in ART-treated HIV-
1-patients with viral suppression before and after 6months of
probiotic supplementation. Moreover, in order to ascertain
the effectiveness of this probiotics in reversing intestinal
barrier injury, we performed a detailed histological and
Figure 6. Intraepithelial lymphocytes (IELs) density in cecum (A), ileum (B), ascending (C), transverse (D), and descending colon (E) biopsies from HIV-
1-infected patients (n¼ 10) who achieved virological suppression in response to ART therapy at enrollment (T0) and after 6 months (T6) of probiotic
supplementation. The results shows a significant reduction of IELs density in cecum, ascending, transverse, and descending colon (T0 vs. T6; P< 0.05).
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morphological evaluation of GALT and intestinal tract
tissues. We found that: (i) a significant reduction of T-cell
activation occurs both in peripheral blood and in the GALT;
(ii) the frequency of CM and EM Th17 cell subsets increases
especially inGALTbut also in the peripheral bloodwhile Tc17
frequencies remained unchanged; (iii) the probiotic im-
proved the integrity of the gut epithelial barrier; (iv) the
probiotic supplementation leads to a reduction of both IELs
density and enterocytes death via apoptosis; and (v) the
probiotic improved mitochondrial morphology trough a
localization of mitochondrial chaperonin, HPS60, from
cytosol to mitochondrial compartment. Last but not least,
consistent with our previous study, we found a clear and
significant reduction in the levels of systemic immune activation
on CD4þ or CD8þ T-cell subsets, defined by CD38þ and
HLA-DRþ markers, after probiotic supplementation [15].
These findings reinforced the concept on the beneficial
impact of this specific probiotic intervention on systemic
immune activation in chronically HIV-1-infected patients.
In this pilot study, we also demonstrated that the reduction
Figure 7. TUNEL apoptosis in HIV-1-infected patients before (T0) and after 6 (T6) months of probiotic supplementation. (A and B) Apoptosis in the colon
epithelium and in lymphocytes infiltrating epithelia at T0 and T6 (10 enlargement). (C and D) Apoptotic nuclei in colonic crypts cells at T0 and T6 (20
enlargement). (E) Detection of apoptosis in mucosal epithelial surface and in the crypts. A significant reduction of apoptosis is observed in both
epithelium and crypts at T6 (T0 vs. T6, P< 0.05, Wilcoxon test).
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Figure 8. Gut HSP60 expression and TEM evaluation of ileum epithelium before (T0) and after 6 months (T6) of probiotic supplementation. HSP60-
positive cells/field in cecum (A), ileum (B), ascending (C), transverse (D), and descending (E) colon biopsies at T0 and T6 P< 0.05 (T0 vs. T6) in ascending,
descending, and transverse colon biopsies. (F) The mitochondrial component is highly edematous, bulgy, with cristolysis areas (see arrow) and
vacuolations (see arrows head) at T0. A recovery of the mitochondrial structures (see asterisk) was recorded at T6 (scale bar¼ 500mm). (G) Immunogold
in the ileum sections: anti-HSP60 antibody-conjugated gold particles are scarcely present in mitochondrial and they are located in extra-mitochondrial
space at T0 (see arrows), conversely anti-HSP60 antibody conjugated gold particles are located in large amount inside the mitochondria at T6 (scale
bar¼ 100 nm).
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of T-cell activation occurs also in the GALT compartment,
indicating that the probiotic intervention is not associated to
an increase of intestinal mucosal inflammation but to a
reduction of the harmful excessive activation of T-cell
immunity in this anatomical site, in agreement with what
recently demonstrated in the colon of in healthy macaques
post probiotic therapy [41]. Remarkably, the reduction of
T-cell activation was accompanied to a strong increase in the
percentage of CM and EM Th17 cells after probiotic
supplementation in both the anatomical sites analyzed. This
increase was particularly evident in the GALT for the CM
Th17 subset (more than 10-fold increase) compared to
peripheral blood (fivefold increase). Moreover, we also
found that the probiotic intervention increased the
percentage of Th1 cell subsets in GALT. The discrepancy
observed between GALT and PBMC compartments in terms
of CD4þ T-cell subsets increased after the probiotic intake
reflects the complexity of gut T-cell depletion observed
during HIV-1 infection. It is known that direct and indirect
viral cytopathic effects, host-derived cellular immune
response, activation-induced cell death and, perhaps,
alterations in mucosal homing, may occur simultaneously.
Also previous studies have shown that circulating T-cell
subset and tissue-specific lymphocytemigration patterns can
occur independently [42–45]. These increased reconstitu-
tions after probiotic therapy are important, considering that
long-term ART-treated HIV-1-infected patients seldom
reconstitute GI tract CD4þ T-cells to healthy levels [46]
probably a cause of alterations in CD4þ T-cell homing to the
gut [47]. In agreement, Klatt et al. [11] have shown that the
probiotic supplementation of SIV-infected pigtail macaques
leads to gut CD4þ T-cell restoration and enhanced Th17
functionality. However, the improvement in the frequency
of Th17 cells seems to be different in SIV infection models
depending on whether the probiotic was supplemented with
IL-21 or not [11, 12]. Conversely to that observed on the
Th17 levels, we found the probiotic intervention did not
affect the percentage of Tc17 in GALT and peripheral blood.
These cells are maintained in the gut of RMs during acute
SIV infection, but they are progressively depleted during
end-stage disease [48, 49]. In order to have a more detailed
view about the action of this probiotic formulation on gut
mucosa, a histomorphological analysis was performed in
multiple intestinal tract tissues biopsies taken from the HIV-
1-positive patients before and after probiotic supplementa-
tion. It is known that histopathologic changes during
HIV-1-related enteropathy include villous blunting and
widen-ing, vacuolated enterocytes, crypt hyperplasia, and
increased inflammatory cells in the lamina propria [50–53].
Similar histopathologic alterations were observed in all the
HIV-1-positive patients before probiotic intervention. The
probiotic supplementation caused histomorphological and
ultrastructural changes of all intestinal tract tissues analyzed
leading to an improvement of epithelial integrity, a
reduction of diffuse interstitial inflammatory infiltrate,
and an increase in the number and area of the GALT
structures. Moreover, a strong reduction in IELs density was
also observed. Notably, Mattapallil et al. [54] reported that
that IELs can support the active replication of SIV and that
their phenotypic profile and function were changed in SIV
infection. The latter aspects could have several implications
on the HIV-1-associated enteropathy and indirectly on the
beneficial effects of probiotic observed on the intestinal
immunity and epithelium barrier repair. Indeed, since the
functions carried out by IELs in the gut mucosa seem to be
mediated in part by the cytokines (i.e., IFNg, tumor necrosis
factor alpha [TNFa], and interleukin-2 [IL-2]) and chemo-
kines (MIP-1b and RANTES) that they produce, these cells
may play a relevant role in regulating the intestinal cytokine
network of HIV-1-infected patients contributing, in a
situation of functional alteration, to the breakdown of the
intestinal immunity [54, 55]. As a matter of fact, high levels
of TNFa are thought to induce enterocytes apoptosis and
supplementation with anti-TNF antibodies is of important
clinical benefit to patients suffering from Crohn’s dis-
ease [56]. Directly related to this aspect, another important
finding of our study was that enterocytes apoptotic index
was found to be considerably downregulated after probiotic
supplementation, indicating a stimulating probiotic action
on gut regrowth and re-epithelization. In agreement,
Mogilner et al. [57] found that probiotic supplementation
causes a decrease in enterocyte apoptosis in a rat model with
massive small bowel resection. The mechanisms underlying
the effects of probiotic on the enterocytes apoptosis are
currently unknown. However, the enterocytes apoptosis rate
in HIV-1-positive patients has been related to the HIV-1
transactivator factor (Tat), through an oxidative stress
mediated mechanism [58] and an antioxidant effects of
probiotic for contrasting the adverse effects of reactive
oxygen species (ROS) on intestinal barrier has been
reported [59]. Alongside the effects of probiotic on reducing
IELs density and enterocytes apoptosis, we found that
epithelial barrier amelioration was strictly related to a
mitochondrial morphological improvement after probiotic
supplementation, and a strong HSP60 expression was
evidenced into mitochondrial matrix by immunogold
technique, associated to a decrease, in absolute sense, in
intracytoplasmic concentration. Interestingly, the cytosolic
accumulation of HSP60 has been shown to represent an
ordinary event during apoptosis induction and that the pro-
death role of HSP60 seems to require caspase-3 maturation
and cytoplasmic activation [60]. Moreover, the presence of
HSP60 in mitochondria of the gastrointestinal tract has been
associated to the followingmechanisms of organelle renewal:
(i) total reformation of mitochondria and their content after
cell division and (ii) regeneration of mitochondrial after
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ATP production [61]. There were any studies on the
evaluation of HSP60 in intestinal tracts of HIV-1-infected
patients; however, in agreement to our finding, it has
been showed that HSP60—classically a mitochondrial
protein—was abundantly also present in cytosol in intestinal
biopsies taken at the time of diagnosis from patients
suffering from ulcerative colitis, but not after the probiotic
supplementation [62].
Although limited in the sample size of HIV-1-infected
patients analyzed due to the necessity to evaluate the
implementation of the novel intervention with a high
concentration multi-strain probiotic in terms of safety,
tolerance, and efficacy, our study represent an important
incentive to justify larger randomized double bind clinical
studies in order to characterize in detail themechanism of the
probiotic action on bothmucosal and systemic immunity, GI
physiology, and viral reservoir and to assess whether probiotic
intervention could improve the prognosis of ART-treated
HIV-1-infected individuals. It will also be important to
evaluate whether the improved immunophenotypic pattern
observed after probiotics treatment remained stable after
cessation of probiotic intake.
At the same time, it should be emphasized that
probiotics are normally made up of a genus (e.g.,
Streptococcus), a species (e.g., thermophilus), and a strain
(e.g., DSM24731); while the genus and species tells us a bit
about its properties, it is the probiotic strain itself which
determines the efficacy of the product and hence the
associated findings. Accordingly, it should be reminded
that the results of our pilot study should not be translated
or generalized to other probiotic formulations differing for
number of live/dead bacteria, strains type or manufactur-
ing processes, especially when the target population is at
risk like ART subjects.
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Figure S1. Consort checklist.
Figure S2. Flow diagram.
Figure S3. Gating strategy for flow cytometry analysis of
peripheral blood and GALT. Singlets were identified by FSC-
A versus FSC-H dot plot (A). After gating on lymphocytes,
identified by the FSC and SSC parameters (B), CD3þCD4þ
and CD3þCD8þ gates were defined (C and D); for both of
them, central memory (CM) and effector memory (EM)
gates were identified by the expression of CD45ro and CD27
(E). CD8 and CD4 lymphocytes and the CM and EM
subpopulations were investigated for the activation status by
the CD38 and HLA-DR expression (F) and for the intra-
citoplasmatic expression of IFN-g (Th1 and Tc1, respec-
tively) and IL-17A (Th17 and Tc17, respectively) (G).
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